Going back to class I: MHC and immunotherapies for childhood cancerKellie B. Haworth, Timothy P. Cripe, Jennifer L. Leddon et al.|Pediatric Blood & Cancer|2014Cited by 86
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L. Leddon, Timothy P. Cripe, Timothy D. Eubank et al.|Molecular Therapy — Oncolytics|2014Cited by 44
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P. Cripe, Gregory K. Friedman, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2015Cited by 22
Characterization of MHC Class I and β‐2‐Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune‐Based Therapeutic TrialsKellie B. Haworth, Timothy P. Cripe, Michael Arnold et al.|Pediatric Blood & Cancer|2015Cited by 16
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K. Friedman, Timothy P. Cripe, Elizabeth A. Beierle et al.|Molecular Therapy — Oncolytics|2015Cited by 13